Physician profile
David B Roy
NPI 1801097019
$9,782.09
in general payments reported to CMS, 2019-2025
35 companies · $1,809 in 2025
The $1,809 reported for 2025 was more than what 87% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,006 · 2020: $779 · 2021: $1,135 · 2022: $1,537 · 2023: $1,770 · 2024: $1,747 · 2025: $1,809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,317 · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,316.50 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,366.06 | 2019-2025 | Rinvoq, Skyrizi, Botox |
| Novartis Pharmaceuticals Corporation | $1,986.89 | 2019-2025 | |
| Genzyme Corporation | $963.21 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $638.51 | 2019-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $456.26 | 2019-2025 | Tremfya, Simponi, Stelara |
| Ucb, INC. | $370.02 | 2020-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $356.53 | 2019-2025 | Ilumya, Blu-U |
| Leo Pharma INC. | $328.19 | 2020-2025 | Adbry |
| Allergan, INC. | $253.29 | 2019-2022 | |
| Galderma Laboratories, L.P. | $247.13 | 2020-2025 | Nemluvio, Dysport |
| Incyte Corporation | $184.27 | 2022-2025 | Opzelura |
| Lilly USA, LLC | $181.60 | 2020-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $170.91 | 2023-2024 | Sotyktu |
| Pfizer INC. | $166.21 | 2019-2025 | |
| Amgen INC. | $121.83 | 2020-2025 | Otezla, Otezla |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $101.58 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Strata Skin Sciences, INC. | $86.92 | 2019-2023 | Xtrac |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $85.03 | 2019-2025 | Cabtreo, Arazlo |
| Revance Therapeutics, INC. | $82.36 | 2024-2025 | Daxxify |
| Dusa Pharmaceuticals, INC. | $82.30 | 2019 | |
| Mayne Pharma Commercial LLC | $71.12 | 2019-2020 | |
| Organon LLC | $55.02 | 2025 | Vtama |
| Genentech USA, INC. | $52.05 | 2021 | |
| Hill Dermaceuticals, INC. | $48.47 | 2021-2023 | Tolak |
| Biowound Solutions, INC. | $44.43 | 2025 | Bio-Connekt |
| Almirall LLC | $41.23 | 2022-2025 | Seysara |
| Mallinckrodt Hospital Products INC. | $39.11 | 2024-2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.48 | 2024-2025 | Spevigo, Cyltezo |
| Dermavant Sciences, INC. | $32.75 | 2023-2024 | Vtama |
| Merz North America, INC. | $32.53 | 2019 | |
| Organogenesis INC. | $30.24 | 2023-2024 | Puraply |
| Convatec INC. | $19.10 | 2024 | |
| Celgene Corporation | $18.92 | 2019 | |
| Botanix Sb INC | $18.07 | 2025 | Sofdra |
| Prugen, INC. Pharmaceuticals | $16.47 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Roy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.